Contents

President’s Message ................................................. 3

AMP Strategic Plan .................................................. 4

  Mission Statement ................................................. 4
  Vision Statement .................................................. 5
  Core Principles ..................................................... 5

2018 Board of Directors and Committee Chairs .................. 6

Affiliations .......................................................... 7

Organizational Relationships ...................................... 7

Advocacy and Clinical Practice .................................... 8

Membership and Annual Meeting Overview ..................... 9

International Education Initiatives ............................... 10

Financial Statement ................................................. 11
Message

FROM THE PRESIDENT

Dear Colleagues,

Diagnostic molecular and genomic approaches are at the forefront of modern medicine. Since 1995, AMP’s community of experts has advanced the clinical practice, science, and excellence of our field to provide the highest quality health care for patients.

Our society brings together an international, diverse and dynamic community: we are molecular pathologists, clinical laboratorians, basic and translational scientists, technologists and trainees. Together, we develop clinical practice guidelines and share ground-breaking research in our academic publication, The Journal of Molecular Diagnostics. We advocate for patients at our places of work, as well as in the halls of government and regulatory agencies. We collaborate to create a comprehensive catalog of educational offerings, and we exchange key knowledge at our professional meetings.

AMP continues to grow and evolve every year. For the first time ever, our membership exceeds 2,500 individuals this year. Our international community grew by a remarkable 20% in 2018, and we now have members practicing in 51 countries.

In 2018, we hosted another exceptional Annual Meeting & Expo in San Antonio, Texas, where all aspects of new molecular testing were discussed. In addition, our Board of Directors decided to host an international meeting every year going forward, in order to engage members and medical professionals around the world. We hosted AMP Europe 2018 this spring in Rotterdam, The Netherlands, and we plan to return to the continent biennially in even years. The AMP Global meeting will move around the globe in odd years, and the next meeting will take place in Hong Kong in 2019.

Serving as your President has been a true honor. I look forward to our community’s continued successes.

Sincerely,

Kojo S. J. Elenitoba-Johnson, MD
AMP President
AMP'S STRATEGIC PLAN IS DYNAMIC.

Implementation success is reviewed and celebrated annually by the Board of Directors, who add and archive strategic objectives as necessary to accommodate the needs associated with this dynamic field. Foundational to its strategic plan are AMP's Mission, Vision, and Core Principles.

MISSION STATEMENT

The ASSOCIATION FOR MOLECULAR PATHOLOGY is a not-for-profit scientific society that advances the CLINICAL PRACTICE, SCIENCE, and EXCELLENCE of molecular and genomic laboratory medicine through EDUCATION, INNOVATION, and ADVOCACY to enable highest quality health care.
VISION STATEMENT

The ASSOCIATION FOR MOLECULAR PATHOLOGY seeks to be a global community of professionals that advances excellence in the clinical practice of molecular and genomic laboratory medicine through:

• Activities that foster INNOVATIVE and TRANSFORMATIVE PATIENT CARE and the translation of scientific discoveries into diagnostic tests and services

• EDUCATION PROGRAMS that promote clinical laboratory testing of high quality and utility

• ADVOCACY that supports the practice of molecular pathology to enhance patient care, addresses regulatory and payment issues, and facilitates the adoption of innovative laboratory testing and technologies

• Activities that facilitate knowledge transfer and COLLABORATION among professionals worldwide

CORE PRINCIPLES

• Quality Health Care Through EXCELLENCE in Clinical Molecular Testing

• Fostering the GLOBAL COMMUNITY of Molecular Pathology Professionals

• COLLABORATION to Advance Molecular Pathology

• ADVOCACY that Advances the Field and Practice of Molecular Pathology, Protects Patients, and Improves the Adoption of Innovative Technologies and Tests

• INNOVATION to Transform Patient Care
2018 BOARD OF DIRECTORS

PRESIDENT
Kojo S. J. Elenitoba-Johnson, MD
University of Pennsylvania, Perelman School of Medicine

PRESIDENT-ELECT
AND STRATEGIC OPPORTUNITIES COMMITTEE CHAIR
Victoria M. Pratt, PhD
Indiana University Medical Center

INFORMATICS SUBDIVISION CHAIR
Alexis B. Carter, MD
Children’s Healthcare of Atlanta

SOLID TUMORS SUBDIVISION CHAIR
Roger D. Klein, MD, JD
Klein & Klein Co. L.P.A

INVITED GUEST
INTERNATIONAL AFFAIRS COMMITTEE CHAIR
Rami Mahfouz, MD, MPH
American University of Beirut Medical Center

EXECUTIVE DIRECTOR
Mary Steele Williams, MNA, MT(ASCP)SM, CAE

PUBLICATION & COMMUNICATION COMMITTEE CHAIR
Paul G. Rothberg, PhD
University Rochester Medical Center

TRAINING & EDUCATION COMMITTEE CHAIR
Cecilia Ching Sze Yeung, MD
Fred Hutchinson Cancer Research Center

GENETICS SUBDIVISION CHAIR
Birgit Funke, PhD
Veritas Genetics

HEMATOPATHOLOGY SUBDIVISION CHAIR
Annette Kim, MD, PhD
Brigham and Women’s Hospital

INFECTION SUBDIVISION CHAIR
David R. Hillyard, MD
ARUP Laboratories, Inc.

PAST PRESIDENT
AND NOMINATING COMMITTEE CHAIR
Federico A. Monzon, MD
Castle Biosciences

EXECUTIVE DIRECTOR
Mary Steele Williams, MNA, MT(ASCP)SM, CAE

SECRETARY-TREASURER
AND FINANCE COMMITTEE CHAIR
Daniel E. Sabath, MD, PhD
University of Washington Medical Center

INFECTION SUBDIVISION CHAIR
David R. Hillyard, MD
ARUP Laboratories, Inc.

CLINICAL PRACTICE COMMITTEE CHAIR
Antonia R. Sepulveda, MD, PhD
Columbia University Medical Center

ECONOMIC AFFAIRS COMMITTEE CHAIR
Samuel K. Caughron, MD
MAWD Pathology Group, PA

MEMBERSHIP AFFAIRS COMMITTEE CHAIR
Ron M. Przygodzki, MD
Department of Veterans Affairs

PROFESSIONAL RELATIONS COMMITTEE CHAIR
Jordan Laser, MD
Northwell Health

PROGRAM COMMITTEE CHAIR
Lynne V. Abruzzo, MD, PhD
Ohio State University Medical Center

INFECTION SUBDIVISION CHAIR
David R. Hillyard, MD
ARUP Laboratories, Inc.
Collaborations

INTERNATIONAL AFFILIATES

The Hong Kong Society for Molecular Diagnostic Sciences (2013)
The Molecular Pathology Association of India (2013)
The Korean Society for Laboratory Medicine (2013)
The German Society of Pathology (2015)
Brazilian Society of Clinical Pathology and Laboratory Medicine (2017)
The Italian Society of Pathology and Translational Medicine (2017)
American University of Beirut Medical Center (2018)

ORGANIZATIONAL RELATIONSHIPS

AMP maintains MEMBERSHIP in the following organizations:
The Pathology Roundtable
Cancer Leadership Council (CLC)
Federation of American Societies for Experimental Biology (FASEB)
Global Alliance for Genomic Medicine
Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC)
Intersociety Pathology Council (IPC)
Personalized Medicine Coalition (PMC)

AMP maintains RELATIONSHIPS with many organizations, including but not limited to:
Representative to ASCO CancerLinQ Steering Committee
Cooperating Society of the American Board of Pathology (ABP)
Steering Committee, NIST Genome in A Bottle Consortium
Associate Member of the Intersociety Council for Pathology Information (ICPI)
Sponsor of the National Academies Roundtable on Genomics and Precision Health
Representatives to FNIH Biomarkers Consortium Steering Committees
Representative to the College of American Pathology Pathology Coding Caucus (PCC)
Representative to the CAP Molecular Oncology Committee
AMP ADVOCATES for excellence in molecular testing in clinical laboratories. We advance the field and practice of molecular pathology by representing the membership to the federal agencies and members of Congress to inform and influence public policy. AMP’s clinical and scientific affairs initiatives aim to transform patient care through INNOVATION.

ADVOCACY

In 2018, AMP led and participated in numerous joint advocacy initiatives, hosted two “lunch and learns” with patient advocates, and held webinars on CPT® coding and changes to PAMA. In addition, AMP submitted over 35 ADVOCACY COMMENT LETTERS on issues such as:

- National Coverage Determination for Next Generation Sequencing for Advanced Cancer Patients
- Draft Bills on Oversight of Laboratory Developed Testing Procedures
- Local Coverage Determinations for Molecular Pathology Procedures
- Protecting Access to Medicare Act (PAMA) Data Reporting and Implementation

INNOVATION & IMPROVED PATIENT CARE

In 2018, over 200 MEMBER VOLUNTEERS worked on AMP efforts to foster excellence in clinical practice and patient care. These efforts included AMP representation on outside collaborative projects or committees, and the publication of four major guideline projects:

Standards and Guidelines for Validating Next-Generation Sequencing Bioinformatics Pipelines

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
J Mol Diagn. 2018 March; 20(2):129-159

Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology
J Mol Diagn. 2018 May; 20(3):269-276

Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology
AMP ended the year with continued membership growth, rising from 2,417 in 2017 to 2,514 in 2018. Indicators suggest that growth will continue for the coming years. AMP members can be found in 51 COUNTRIES.

Attendance continued to be strong at the 2018 ANNUAL MEETING. We welcomed 2,100 attendees and approximately 190 companies. In addition, we welcomed over 300 attendees and 30 exhibiting companies at AMP EUROPE.

<table>
<thead>
<tr>
<th>YEAR</th>
<th>LOCATION</th>
<th>SCIENTIFIC ATTENDEES</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>GAYLORD TEXAN, TX</td>
<td>1,343</td>
</tr>
<tr>
<td>2012</td>
<td>LONG BEACH, CA</td>
<td>1,674</td>
</tr>
<tr>
<td>2013</td>
<td>PHOENIX, AZ</td>
<td>1,720</td>
</tr>
<tr>
<td>2014</td>
<td>WASHINGTON, DC</td>
<td>1,944</td>
</tr>
<tr>
<td>2015</td>
<td>AUSTIN, TX</td>
<td>2,084</td>
</tr>
<tr>
<td>2016</td>
<td>CHARLOTTE, NC</td>
<td>2,022</td>
</tr>
<tr>
<td>2017</td>
<td>SALT LAKE CITY, UT</td>
<td>2,201</td>
</tr>
<tr>
<td>2018</td>
<td>SAN ANTONIO, TX</td>
<td>2,106</td>
</tr>
</tbody>
</table>

AMP MEMBERS BY DEGREE:

PhD 875 (34.8%)
MD 1074 (42.7%)
Other 565 (22.5%)
AMP’s educational initiatives continue to reach a global audience. In 2018, AMP hosted its first AMP EUROPE meeting in Rotterdam, THE NETHERLANDS. AMP invited speakers also presented at two AMP-affiliate society conferences in Bhubaneshwar, INDIA and Seoul, KOREA. In addition, AMP hosted a luncheon for international attendees at the AMP 2018 Annual Meeting.

AMP received support to organize two webinar series in 2018: a 5-part series on Advancing Patient Care in NSCLC: Breaking Down Barriers and a 3-part series on Tumor Mutational Burden: Challenges and Opportunities for Improving Cancer Patient Care. These free programs (and their complimentary continuing education credit) are available through 2020.

The AMP learning management system, AMPED™, has more than 150 hours of cutting-edge molecular pathology content delivered by experts in the field. To learn more, visit educate.amp.org.
AMP’s fiscal footing is solid, allowing it to dedicate significant resources to each of its strategic initiatives.

<table>
<thead>
<tr>
<th>STRATEGIC INITIATIVE</th>
<th>2018</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advocacy</td>
<td>$(490,772)</td>
<td>$(437,181)</td>
<td>$(426,435)</td>
</tr>
<tr>
<td>Communications &amp; Outreach</td>
<td>$(125,071)</td>
<td>$(193,658)</td>
<td>$(174,649)</td>
</tr>
<tr>
<td>Education</td>
<td>$2,021,273</td>
<td>$1,932,749</td>
<td>$2,299,693</td>
</tr>
<tr>
<td>Innovation &amp; Improved Patient Care</td>
<td>$(250,296)</td>
<td>$(288,701)</td>
<td>$(290,237)</td>
</tr>
<tr>
<td>Membership &amp; Management Services</td>
<td>$(220,128)</td>
<td>$(208,213)</td>
<td>$(32,781)</td>
</tr>
</tbody>
</table>

**EXCESS REVENUE OVER EXPENSES**

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>$935,006</strong></td>
<td><strong>$804,996</strong></td>
<td><strong>$1,375,591</strong></td>
<td></td>
</tr>
</tbody>
</table>